WO2003082908A3 - Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein - Google Patents

Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein Download PDF

Info

Publication number
WO2003082908A3
WO2003082908A3 PCT/EP2003/003177 EP0303177W WO03082908A3 WO 2003082908 A3 WO2003082908 A3 WO 2003082908A3 EP 0303177 W EP0303177 W EP 0303177W WO 03082908 A3 WO03082908 A3 WO 03082908A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
protein
p17
medicament
use
Prior art date
Application number
PCT/EP2003/003177
Other languages
French (fr)
Other versions
WO2003082908A2 (en
Inventor
Arnaldo Caruso
Original Assignee
Medestea Internaz S R L
Arnaldo Caruso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IT2002TO000286A priority Critical patent/ITTO20020286A1/en
Priority to ITTO2002A000286 priority
Application filed by Medestea Internaz S R L, Arnaldo Caruso filed Critical Medestea Internaz S R L
Publication of WO2003082908A2 publication Critical patent/WO2003082908A2/en
Publication of WO2003082908A3 publication Critical patent/WO2003082908A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • A61K2039/55527Interleukins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention relates to a medicament for booster antigen use in HIV seropositive patients which uses, as active ingredient, the p17 protein of HIV or variants thereof in isolated or DNA form, containing sequences encoding for p17 or its variants which, if administered alone or combined with anti-inflammatory cytokines and molecules or DNA encoding for anti-inflammatory cytokines, are able to evoke or increase the serum titre of the anti-HIV-p17 antibodies that are capable of neutralizing the immunostimulating activity of the viral protein.
PCT/EP2003/003177 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein WO2003082908A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT2002TO000286A ITTO20020286A1 (en) 2002-03-29 2002-03-29 Use of isolated p17 protein for the preparation of a medicament act to inhibit the immunostimulatory effects that the protein produced d
ITTO2002A000286 2002-03-29

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003219101A AU2003219101A1 (en) 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein

Publications (2)

Publication Number Publication Date
WO2003082908A2 WO2003082908A2 (en) 2003-10-09
WO2003082908A3 true WO2003082908A3 (en) 2004-03-25

Family

ID=27638968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003177 WO2003082908A2 (en) 2002-03-29 2003-03-27 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein

Country Status (3)

Country Link
AU (1) AU2003219101A1 (en)
IT (1) ITTO20020286A1 (en)
WO (1) WO2003082908A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20080027A1 (en) 2008-01-15 2009-07-16 Medestea Res & Production S P A Truncated form of the protein p17 of HIV.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293792A2 (en) * 1987-06-01 1988-12-07 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus GAG-encoded proteins
EP0322394A2 (en) * 1987-11-24 1989-06-28 Smithkline Biologicals S.A. Expression of HIV proteins in E. coli and S. cerevisiae
WO1998037089A2 (en) * 1997-02-24 1998-08-27 Oxford Biomedica (Uk) Limited Matrix derived anti-hiv peptides and transdominant proteins
WO2003016337A1 (en) * 2001-08-07 2003-02-27 Medestea Internazionale S.R.L. Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293792A2 (en) * 1987-06-01 1988-12-07 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus GAG-encoded proteins
EP0322394A2 (en) * 1987-11-24 1989-06-28 Smithkline Biologicals S.A. Expression of HIV proteins in E. coli and S. cerevisiae
WO1998037089A2 (en) * 1997-02-24 1998-08-27 Oxford Biomedica (Uk) Limited Matrix derived anti-hiv peptides and transdominant proteins
WO2003016337A1 (en) * 2001-08-07 2003-02-27 Medestea Internazionale S.R.L. Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARUSO ARNALDO ET AL: "HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor", FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), Annual Meeting of the Professional Research Scientists on Experimental Biology;New Orleans, Louisiana, USA; April 20-24, 2002, pages A294, XP009019455, ISSN: 0892-6638 *
FERNANDES J C ET AL: "THE ROLE CYTOKINES IN OSTEOARTHRITIS PATHOPHYSIOLOGY", BIORHEOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 39, no. 1/2, April 2001 (2001-04-01), pages 237 - 246, XP008009498, ISSN: 0006-355X *
FRANCESCO DE M A ET AL: "HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 99, no. 15, 23 July 2002 (2002-07-23), pages 9972 - 9977, XP002234153, ISSN: 0027-8424 *
KIM J J ET AL: "CYTOKINE MOLECULAR ADJUVANTS MODULATE IMMUNE RESPONSES INDUCED BY DNA VACCINE CONSTRUCTS FOR HIV-1 AND SIV", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 19, no. 1, January 1999 (1999-01-01), pages 77 - 84, XP000971666, ISSN: 1079-9907 *
ORLIKOWSKY THORSTEN W ET AL: "Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons", JOURNAL OF INFECTIOUS DISEASES, vol. 184, no. 10, 15 November 2001 (2001-11-15), pages 1328 - 1330, XP002258403, ISSN: 0022-1899 *

Also Published As

Publication number Publication date
ITTO20020286A1 (en) 2003-09-29
WO2003082908A2 (en) 2003-10-09
AU2003219101A1 (en) 2003-10-13
AU2003219101A8 (en) 2003-10-13
ITTO20020286D0 (en) 2002-03-29

Similar Documents

Publication Publication Date Title
RU2404189C9 (en) Novel peptides as inhibitors of hepatitis c virus ns3-serine protease
RU2441878C2 (en) Vaccine for prevention and treatment of hiv-infection
GB2374010B (en) Novel vitamin B12 - biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
Hilleman Immunologic, chemotherapeutic and interferon approaches to control of viral disease
DK1636236T3 (en) Pyrazolo-quinazoline derivatives, to a process for their preparation, and their use as kinase inhibitors
WO2009044273A3 (en) Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
TW200413361A (en) New compounds
WO2003070236A3 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
CA2442865A1 (en) Vaccine composition
BRPI0408125A (en) 1-amino-1H-imidazoquinoline
CY1118991T1 (en) Formulations Human antibodies for treatment relating to tnf-alpha DISORDERS
WO2003077834A3 (en) Central airway administration for systemic delivery of therapeutics
DE122011100053I1 (en) Influenza vaccine compositions for intradermal administration.
EE200300338A (en) Nukleosiidühend, a pharmaceutical composition comprising the compound, and the use of the viral RNA-dependent RNA polymerase inhibitor in the manufacture of a medicament effective
WO2004043363A3 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
UA83458C2 (en) The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
HUE027064T2 (en) Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BRPI0407001A (en) A method for increasing the stability of a purified protein, using a protein active site-specific binder, the method for increasing production of a recombinant protein pharmaceutical composition and
WO2003082853A8 (en) New compounds
SA2510B1 (en) Novel Compounds For Use in the Treatment of Bacterial Infections
BR9911071A (en) Preparations for the application of anti-inflammatory agents, especially antiseptic and / or promoters of wound healing in the upper respiratory tract and / or ear
DK1283700T3 (en) Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds
BR0206695A (en) epothilones dosage forms for oral administration

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP